Logo image of DNAB

SOCIAL CAPITAL SUVRETTA HO-A (DNAB) Stock Fundamental Analysis

NASDAQ:DNAB - Nasdaq - KYG8253U1031 - Common Stock - Currency: USD

10.35  +0.01 (+0.1%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DNAB. DNAB was compared to 0 industry peers in the Unkown industry. The financial health of DNAB is average, but there are quite some concerns on its profitability. DNAB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DNAB was profitable.
DNAB had a negative operating cash flow in the past year.
DNAB Yearly Net Income VS EBIT VS OCF VS FCFDNAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 0 1M -1M 2M

1.2 Ratios

Industry RankSector Rank
ROA 2.11%
ROE 2.18%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DNAB Yearly ROA, ROE, ROICDNAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 0.2 -0.2 0.4 0.6 0.8 1

1.3 Margins

DNAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNAB Yearly Profit, Operating, Gross MarginsDNAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

DNAB has about the same amout of shares outstanding than it did 1 year ago.
DNAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DNAB Yearly Shares OutstandingDNAB Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 10M 20M 30M
DNAB Yearly Total Debt VS Total AssetsDNAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 25.00 indicates that DNAB is not in any danger for bankruptcy at the moment.
There is no outstanding debt for DNAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25
ROIC/WACCN/A
WACCN/A
DNAB Yearly LT Debt VS Equity VS FCFDNAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

DNAB has a Current Ratio of 0.98. This is a bad value and indicates that DNAB is not financially healthy enough and could expect problems in meeting its short term obligations.
DNAB has a Quick Ratio of 0.98. This is a bad value and indicates that DNAB is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
DNAB Yearly Current Assets VS Current LiabilitesDNAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 200K 400K 600K 800K

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 822.31% over the past year.
EPS 1Y (TTM)822.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1287.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DNAB Yearly Revenue VS EstimatesDNAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022
DNAB Yearly EPS VS EstimatesDNAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNAB is valuated quite expensively with a Price/Earnings ratio of 60.88.
When comparing the Price/Earnings ratio of DNAB to the average of the S&P500 Index (29.53), we can say DNAB is valued expensively.
Industry RankSector Rank
PE 60.88
Fwd PE N/A
DNAB Price Earnings VS Forward Price EarningsDNAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNAB Per share dataDNAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOCIAL CAPITAL SUVRETTA HO-A

NASDAQ:DNAB (6/30/2023, 8:08:49 PM)

10.35

+0.01 (+0.1%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.58%
Inst Owner Change-28.36%
Ins Owners2.01%
Ins Owner Change0%
Market Cap330.06M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 60.88
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)0.17
EY1.64%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS7.8
TBVpS7.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.11%
ROE 2.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z 25
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)822.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1287.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.7%
OCF growth 3YN/A
OCF growth 5YN/A